The Evaluation of Renal Iron Deposition With a 3 Tesla MRI Device in Beta-Thalassemia Major Patients

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Apr 17

PMID 37065363

Authors

Tevfik Guzelbey

Zeynep Ece Demirbas

Bengi Gurses

Affiliations

Soon will be listed here.

Abstract

Background and objective Beta-thalassemia is the most frequent monogenic disease in the world. In beta-thalassemia major (BTM) patients, blood transfusions for severe anemia usually cause iron overload, leading to increased morbidity and mortality. In this study, we aimed to examine the iron overload in the kidneys of BTM patients with a 3 Tesla (3T) MRI device and assess the relationship between iron overload in the liver and heart as well as serum ferritin levels. Methods This was a retrospective study covering the period between November 2014 and March 2015. MRI was performed on 21 patients with BTM who were receiving blood transfusions and chelation therapy. The control group (n=11) included healthy volunteers. A 3T MRI device (Ingenia, Philips, Best, The Netherlands) using a 16-channel phased array SENSE-compatible torso coil was used. Three-point DIXON (mDIXON) sequence and the relaxometry method were employed to measure iron overload. Both kidneys were analyzed via mDIXON sequence for atrophy or variations. Afterward, the images in which renal parenchyma could be distinguished best were selected. Iron deposition was analyzed via the relaxometry method using a unique software (CMR Tools, London, UK). All data were analyzed using IBM SPSS Statistics v.21 (IBM Corp., Armonk, NY). The Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney U test, and Pearson's and Spearman's rho correlation coefficient were used. A p-value <0.05 was considered statistically significant. Results There was a statistically significant relationship between beta-thalassemia patients who had cardiac iron deposition and those who did not in terms of T2* time (p=0.02). In contrast, there was no similar relationship for liver iron deposition (p>0.05). Renal T2* values were significantly different between the patient and control groups (p=0.029). T2* times were significantly different between patients who had ferritin levels below 2500 ng/ml and those with ferritin levels above 2500 ng/ml (p=0.042). Conclusion Based on our findings, 3T MRI is a safe and reliable tool for screening iron overload in BTM patients as it makes distinguishing between renal parenchyma and renal sinus much easier and as it is more sensitive to iron deposition.

Citing Articles

Advances of Iron and Ferroptosis in Diabetic Kidney Disease.

Chu J, Wang K, Lu L, Zhao H, Hu J, Xiao W Kidney Int Rep. 2024; 9(7):1972-1985.

PMID: 39081773 PMC: 11284386. DOI: 10.1016/j.ekir.2024.04.012.

References

LANDING B, Gonick H, Nadorra R, Hyman C, Wells T, Mersch J . Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol. 1989; 9(5):479-500. DOI: 10.3109/15513818909026908. View

Storey P, Thompson A, Carqueville C, Wood J, de Freitas R, Rigsby C . R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007; 25(3):540-7. PMC: 2884049. DOI: 10.1002/jmri.20816. View

Porter J . Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin. 2009; 33 Suppl 1:S37-45. DOI: 10.3109/03630260903346627. View

Elalfy M, Elsherif N, Ebeid F, Rahman Ismail E, Ahmed K, Darwish Y . Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy. Eur J Radiol. 2018; 103:65-70. DOI: 10.1016/j.ejrad.2018.04.007. View

Pennell D, Porter J, Cappellini M, Chan L, El-Beshlawy A, Aydinok Y . Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012; 97(6):842-8. PMC: 3366648. DOI: 10.3324/haematol.2011.049957. View

Hashemieh M, Azarkeivan A, Akhlaghpoor S, Shirkavand A, Sheibani K . T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Arch Iran Med. 2012; 15(2):91-4. DOI: 012152/AIM.009. View

Wood J, Enriquez C, Ghugre N, Tyzka J, Carson S, Nelson M . MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 106(4):1460-5. PMC: 1895207. DOI: 10.1182/blood-2004-10-3982. View

Aldudak B, Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I . Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000; 15(1-2):109-12. DOI: 10.1007/s004670000434. View

Patel I, Davidson J, Nikolic B, Salazar G, Schwartzberg M, Walker T . Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012; 23(6):727-36. DOI: 10.1016/j.jvir.2012.02.012. View

10.

Weatherall D . The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010; 115(22):4331-6. PMC: 2881491. DOI: 10.1182/blood-2010-01-251348. View

11.

Wood J, Ghugre N . Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin. 2008; 32(1-2):85-96. PMC: 2884397. DOI: 10.1080/03630260701699912. View

12.

Mavrogeni S, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G . A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005; 75(3):241-7. DOI: 10.1111/j.1600-0609.2005.00474.x. View

13.

Papakonstantinou O, Alexopoulou E, Economopoulos N, Benekos O, Kattamis A, Kostaridou S . Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major. J Magn Reson Imaging. 2009; 29(4):853-9. DOI: 10.1002/jmri.21707. View

14.

Wood J, Michael Tyszka J, Carson S, Nelson M, Coates T . Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2003; 103(5):1934-6. DOI: 10.1182/blood-2003-06-1919. View

15.

Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A . Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int. 1994; 46(2):467-70. DOI: 10.1038/ki.1994.295. View

16.

Cappellini M, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2005; 107(9):3455-62. DOI: 10.1182/blood-2005-08-3430. View

17.

Galanello R, Origa R . Beta-thalassemia. Orphanet J Rare Dis. 2010; 5:11. PMC: 2893117. DOI: 10.1186/1750-1172-5-11. View

18.

Hashemieh M, Radfar M, Azarkeivan A, Tabatabaei S, Nikbakht S, Yaseri M . Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res. 2017; 11(2):133-138. PMC: 5575726. View

19.

Schein A, Enriquez C, Coates T, Wood J . Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging. 2008; 28(3):698-704. PMC: 2597353. DOI: 10.1002/jmri.21490. View

20.

Guzelbey T, Gurses B, Ozturk E, Ozveren O, Sarsilmaz A, Karasu E . Evaluation of Iron Deposition in the Adrenal Glands of β Thalassemia Major Patients Using 3-Tesla MRI. Iran J Radiol. 2016; 13(3):e36375. PMC: 5107262. DOI: 10.5812/iranjradiol.36375. View